Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting
Authors
Keywords
-
Journal
PROSTATE
Volume 80, Issue 15, Pages 1273-1296
Publisher
Wiley
Online
2020-08-31
DOI
10.1002/pros.24056
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Investigating PSMA-targeted radioligand therapy efficacy as a function of cellular PSMA levels and intra-tumoral PSMA heterogeneity
- (2020) Kyle Current et al. CLINICAL CANCER RESEARCH
- Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617
- (2020) Justin Ferdinandus et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).
- (2020) Scott T. Tagawa et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5.
- (2020) Julie Nicole Graff et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase II study of sipuleucel-T (SipT) with or without radium-223 (Ra223) in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC).
- (2020) Catherine Handy Marshall et al. JOURNAL OF CLINICAL ONCOLOGY
- Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer
- (2020) Shankar Siva et al. Nature Reviews Urology
- 225Ac-PSMA-617 for Therapy of Prostate Cancer
- (2020) Clemens Kratochwil et al. SEMINARS IN NUCLEAR MEDICINE
- Mechanistic Insights for Optimizing PSMA Radioligand Therapy
- (2020) Aravind S. Ravi Kumar et al. CLINICAL CANCER RESEARCH
- PSMA Expression in the Neovasculature Associated With Rectal Adenocarcinoma
- (2020) Ida Sonni et al. CLINICAL NUCLEAR MEDICINE
- Overall survival after 177Lu-PSMA-617 molecular radiotherapy in patients with metastatic castrate-resistant prostate cancer: Post-hoc analysis of a prospective phase II trial.
- (2020) Jeremie Calais et al. JOURNAL OF CLINICAL ONCOLOGY
- TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).
- (2020) Michael S Hofman et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR).
- (2020) Michael J. Morris et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial.
- (2020) Michael J. Morris et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).
- (2020) Scott T. Tagawa et al. JOURNAL OF CLINICAL ONCOLOGY
- Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
- (2020) Michael S Hofman et al. LANCET
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings
- (2020) Felipe de Galiza Barbosa et al. CANCER IMAGING
- CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
- (2020) Elaine Sanij et al. Nature Communications
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer
- (2020) Ryan Phillips et al. JAMA Oncology
- Phase I trial of docetaxel plus lutetium-177-labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer
- (2020) Jaspreet S. Batra et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
- (2019) Jeremie Calais et al. BMC CANCER
- Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer
- (2019) Wolfgang P. Fendler et al. JAMA Oncology
- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
- (2019) Triparna Sen et al. Cancer Discovery
- Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls
- (2019) Sara Sheikhbahaei et al. SEMINARS IN NUCLEAR MEDICINE
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Matthew Smith et al. LANCET ONCOLOGY
- Detection Rate of 18F-choline-PET/CT and 68Ga-PSMA-HBED-CC-PET/CT for Prostate Cancer Lymph Node Metastases with Direct Link from PET to Histopathology: Dependence on the Size of Tumor Deposits in Lymph Nodes
- (2019) Cordula Annette Jilg et al. JOURNAL OF NUCLEAR MEDICINE
- Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).
- (2019) Padmanee Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical and molecular analysis of patients treated with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy.
- (2019) Vincenza Conteduca et al. JOURNAL OF CLINICAL ONCOLOGY
- Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis
- (2019) Marlon Perera et al. EUROPEAN UROLOGY
- Going nuclear - It is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team
- (2019) Declan G Murphy et al. BJU INTERNATIONAL
- Phase 1/2 study of fractionated dose lutetium‐177–labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 ( 177 Lu‐J591) for metastatic castration‐resistant prostate cancer
- (2019) Scott T. Tagawa et al. CANCER
- Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis.
- (2019) Bertrand F. Tombal et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT).
- (2019) Panagiotis J. Vlachostergios et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.
- (2019) Johann S. De Bono et al. JOURNAL OF CLINICAL ONCOLOGY
- RESIST-PC phase 2 trial: 177Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer.
- (2019) Jeremie Calais et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection Rate of 18F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis
- (2019) Giorgio Treglia et al. Cancers
- Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series
- (2019) Isaac Goncalves et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Matched-pair comparison of 68Ga-PSMA-11 and 18F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy
- (2019) Isabel Rauscher et al. JOURNAL OF NUCLEAR MEDICINE
- 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial
- (2019) Jeremie Calais et al. LANCET ONCOLOGY
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
- (2019) Ronald de Wit et al. NEW ENGLAND JOURNAL OF MEDICINE
- 849PDPreliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)
- (2019) S T Tagawa et al. ANNALS OF ONCOLOGY
- 846PDPreliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses
- (2019) W Abida et al. ANNALS OF ONCOLOGY
- PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review
- (2019) Christophe Van de Wiele et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
- (2019) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Intraindividual comparison of 18F-PSMA-1007 with renally excreted PSMA ligands for PSMA-PET imaging in patients with relapsed prostate cancer
- (2019) Felix Dietlein et al. JOURNAL OF NUCLEAR MEDICINE
- 18F-DCFPyL PET/CT Imaging in Patients with Biochemical Recurrence Prostate Cancer after Primary Local Therapy
- (2019) Esther Mena et al. JOURNAL OF NUCLEAR MEDICINE
- Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 (177Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer
- (2019) John Violet et al. JOURNAL OF NUCLEAR MEDICINE
- Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies
- (2019) Amir Iravani et al. PROSTATE CANCER AND PROSTATIC DISEASES
- AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
- (2019) Jacqueline H. L. Fok et al. Nature Communications
- Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer
- (2019) Ewa Witkowska-Patena et al. CLINICAL NUCLEAR MEDICINE
- Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Post-treatment SPECT/CT: A Novel Methodology to Generate Time- and Tissue-specific Dose Factors
- (2019) Price A Jackson et al. JOURNAL OF NUCLEAR MEDICINE
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
- (2019) Joaquin Mateo et al. LANCET ONCOLOGY
- Radiobiology: Foundation and New Insights in Modeling Brachytherapy Effects
- (2019) Pierre Annede et al. SEMINARS IN RADIATION ONCOLOGY
- Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors
- (2018) James Kelly et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Targeting PSMA by radioligands in non-prostate disease—current status and future perspectives
- (2018) Philipp Backhaus et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion
- (2018) Kambiz Rahbar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Quantitative characterisation of clinically significant intra-prostatic cancer by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11
- (2018) Liran Domachevsky et al. EUROPEAN RADIOLOGY
- PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA–targeted PET Imaging Studies
- (2018) Steven P. Rowe et al. EUROPEAN UROLOGY
- Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
- (2018) Piet Ost et al. JOURNAL OF CLINICAL ONCOLOGY
- Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms
- (2018) Roberto A. Salas Fragomeni et al. JOURNAL OF NUCLEAR MEDICINE
- A Prospective Comparison of18F-Sodium Fluoride PET/CT and PSMA-targeted18F-DCFBC PET/CT in Metastatic Prostate Cancer
- (2018) Stephanie A Harmon et al. JOURNAL OF NUCLEAR MEDICINE
- 68Ga-PSMA-HBED-CC uptake in cervical, coeliac and sacral ganglia as an important pitfall in prostate cancer PET imaging
- (2018) Christoph Rischpler et al. JOURNAL OF NUCLEAR MEDICINE
- 68 Ga-PSMA Positron Emission Tomography/Computerized Tomography for Primary Diagnosis of Prostate Cancer in Men with Contraindications to or Negative Multiparametric Magnetic Resonance Imaging: A Prospective Observational Study
- (2018) Egesta Lopci et al. JOURNAL OF UROLOGY
- Prostate Specific Membrane Antigen Targeted 18 F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study
- (2018) Michael A. Gorin et al. JOURNAL OF UROLOGY
- [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
- (2018) Michael S Hofman et al. LANCET ONCOLOGY
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group
- (2018) Andrea K. Miyahira et al. PROSTATE
- Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer
- (2018) Karim Boudadi et al. Oncotarget
- Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer
- (2018) Dana E. Rathkopf et al. JAMA Oncology
- Deep Learning Renal Segmentation for Fully Automated Radiation Dose Estimation in Unsealed Source Therapy
- (2018) Price Jackson et al. Frontiers in Oncology
- Detection efficacy of [18F]PSMA-1007 PET/CT in 251 Patients with biochemical recurrence after radical prostatectomy
- (2018) Frederik L. Giesel et al. JOURNAL OF NUCLEAR MEDICINE
- Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging
- (2018) Rudolf A. Werner et al. JOURNAL OF NUCLEAR MEDICINE
- Gallium 68-PSMA PET/CT for lesion characterization in suspected cases of prostate carcinoma
- (2018) Arun Sasikumar et al. NUCLEAR MEDICINE COMMUNICATIONS
- 799PDPhase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)
- (2018) S T Tagawa et al. ANNALS OF ONCOLOGY
- Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer
- (2018) Matthias M. Heck et al. EUROPEAN UROLOGY
- T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
- (2018) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- A Single Dose of 225Ac-RPS-074 Induces a Complete Tumor Response in a LNCaP Xenograft Model
- (2018) James M. Kelly et al. JOURNAL OF NUCLEAR MEDICINE
- Rapid modulation of PSMA expression by Androgen deprivation: Serial 68Ga PSMA-11 PET in men with hormone sensitive and castrate resistant prostate cancer commencing androgen blockade.
- (2018) Louise M Emmett et al. JOURNAL OF NUCLEAR MEDICINE
- Dosimetry of Lu-177 PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pre-therapeutic imaging and “whole body” tumor dosimetry with treatment outcomes
- (2018) John A Violet et al. JOURNAL OF NUCLEAR MEDICINE
- Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer?
- (2018) Emre Demirci et al. NUCLEAR MEDICINE COMMUNICATIONS
- A comparison of prostate cancer bone metastases on 18F-Sodium Fluoride and Prostate Specific Membrane Antigen (18F-PSMA) PET/CT: Discordant uptake in the same lesion
- (2018) Stephanie A Harmon et al. Oncotarget
- Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
- (2018) Katharina Lückerath et al. EJNMMI Research
- 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour
- (2017) Christian Uprimny et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Radiation fractionation: the search for isoeffect relationships and mechanisms
- (2017) John E. Moulder et al. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
- (2017) Tomasz M. Beer et al. JOURNAL OF CLINICAL ONCOLOGY
- Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors
- (2017) Charalambos Kaittanis et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Utility of 68 Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma
- (2017) Shankar Siva et al. Journal of Medical Imaging and Radiation Oncology
- Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
- (2017) Matthias Eiber et al. JOURNAL OF NUCLEAR MEDICINE
- Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer
- (2017) James M. Kelly et al. JOURNAL OF NUCLEAR MEDICINE
- Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen–Targeted PET Imaging: PSMA-RADS Version 1.0
- (2017) Steven P. Rowe et al. JOURNAL OF NUCLEAR MEDICINE
- 177 Lu-PSMA Radioligand Therapy for Prostate Cancer
- (2017) Wolfgang P. Fendler et al. JOURNAL OF NUCLEAR MEDICINE
- 68Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters
- (2017) Stefan A. Koerber et al. JOURNAL OF NUCLEAR MEDICINE
- Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers
- (2017) Kedar Hastak et al. Oncotarget
- Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer
- (2017) Florian C. Gaertner et al. Oncotarget
- Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer
- (2017) Cordula A. Jilg et al. Theranostics
- A dextran-based probe for the targeted magnetic resonance imaging of tumours expressing prostate-specific membrane antigen
- (2017) Guanshu Liu et al. Nature Biomedical Engineering
- PSMA-Based Detection of Prostate Cancer Bone Lesions With 18 F-DCFPyL PET/CT: A Sensitive Alternative to 99m Tc-MDP Bone Scan and Na 18 F PET/CT?
- (2016) Steven P. Rowe et al. Clinical Genitourinary Cancer
- Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer
- (2016) Kambiz Rahbar et al. CLINICAL NUCLEAR MEDICINE
- 18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial
- (2016) Cristina Nanni et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 68Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging
- (2016) Thorsten Derlin et al. EUROPEAN RADIOLOGY
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Accuracy and agreement of PIRADSv2 for prostate cancer mpMRI: A multireader study
- (2016) Matthew D. Greer et al. JOURNAL OF MAGNETIC RESONANCE IMAGING
- First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake
- (2016) N. Pandit-Taskar et al. JOURNAL OF NUCLEAR MEDICINE
- German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
- (2016) Kambiz Rahbar et al. JOURNAL OF NUCLEAR MEDICINE
- PSA-Stratified Performance of 18 F- and 68 Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer
- (2016) Felix Dietlein et al. JOURNAL OF NUCLEAR MEDICINE
- 225Ac-PSMA-617 for PSMA-Targeted -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- Preliminary evaluation of prostate-targeted radiotherapy using131I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs
- (2016) Mathias Tesson et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Current use of PSMA–PET in prostate cancer management
- (2016) Tobias Maurer et al. Nature Reviews Urology
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- (2016) Colin C. Pritchard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Is There Use for FDG-PET in Prostate Cancer?
- (2016) Hossein Jadvar SEMINARS IN NUCLEAR MEDICINE
- Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate
- (2016) Michael T. Schweizer et al. Oncotarget
- Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer
- (2016) Wolfgang P. Fendler et al. Oncotarget
- Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
- (2016) Julie N. Graff et al. Oncotarget
- Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
- (2016) Hojjat Ahmadzadehfar et al. Oncotarget
- Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response
- (2016) Tiejun Li et al. Scientific Reports
- Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
- (2016) Julie Nonnekens et al. Theranostics
- Synthesis and Evaluation of GdIII-Based Magnetic Resonance Contrast Agents for Molecular Imaging of Prostate-Specific Membrane Antigen
- (2015) Sangeeta Ray Banerjee et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
- (2015) N. Pandit-Taskar et al. CLINICAL CANCER RESEARCH
- Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer
- (2015) Andreas Delker et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results
- (2015) Michael J. Morris et al. JOURNAL OF CLINICAL ONCOLOGY
- MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy
- (2015) M. Ljungberg et al. JOURNAL OF NUCLEAR MEDICINE
- Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy
- (2015) J. J. Morigi et al. JOURNAL OF NUCLEAR MEDICINE
- Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer
- (2015) M. Bene ova et al. JOURNAL OF NUCLEAR MEDICINE
- Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
- (2015) Markus Dietlein et al. MOLECULAR IMAGING AND BIOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer
- (2014) B. P. Neuman et al. CLINICAL CANCER RESEARCH
- Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
- (2014) Christian M. Zechmann et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
- (2014) Liufu Deng et al. IMMUNITY
- Impact of 18F-Fluoride PET in Patients with Known Prostate Cancer: Initial Results from the National Oncologic PET Registry
- (2014) B. E. Hillner et al. JOURNAL OF NUCLEAR MEDICINE
- Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
- (2014) Oliver Sartor et al. LANCET ONCOLOGY
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
- (2013) S. T. Tagawa et al. CLINICAL CANCER RESEARCH
- An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging
- (2013) Price A. Jackson et al. MEDICAL PHYSICS
- A Hormone-DNA Repair Circuit Governs the Response to Genotoxic Insult
- (2013) J. F. Goodwin et al. Cancer Discovery
- Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers
- (2013) W. R. Polkinghorn et al. Cancer Discovery
- Bone Marrow Recovery and Subsequent Chemotherapy Following Radiolabeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Men with Metastatic Castration-Resistant Prostate Cancer
- (2013) Scott T. Tagawa et al. Frontiers in Oncology
- Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography
- (2012) Alejandro Sanchez-Crespo APPLIED RADIATION AND ISOTOPES
- 68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging
- (2012) Matthias Eder et al. BIOCONJUGATE CHEMISTRY
- Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
- (2012) Christopher J Logothetis et al. LANCET ONCOLOGY
- The DNA damage response and cancer therapy
- (2012) Christopher J. Lord et al. NATURE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer
- (2012) Anna R. Kwilas Frontiers in Oncology
- The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy
- (2011) Jean-Mathieu Beauregard et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Dose-Fractionation Sensitivity of Prostate Cancer Deduced From Radiotherapy Outcomes of 5,969 Patients in Seven International Institutional Datasets: α/β = 1.4 (0.9–2.2) Gy
- (2011) Raymond Miralbell et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial
- (2011) David Dearnaley et al. LANCET ONCOLOGY
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- Trastuzumab Pharmacokinetics Influenced by Extent Human Epidermal Growth Factor Receptor 2–Positive Tumor Load
- (2010) Thijs H. Oude Munnink et al. JOURNAL OF CLINICAL ONCOLOGY
- A Portable Albumin Binder from a DNA-Encoded Chemical Library
- (2008) Christoph E. Dumelin et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started